Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATXINASDAQ:CYTONASDAQ:PBLANASDAQ:TENX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.12+20.6%$0.15$0.09▼$1.25$5.18M-0.244.61 million shs9.91 million shsCYTOAltamira Therapeutics$1.60+11.1%$1.86$1.35▼$28.40$2.53M1.79985,003 shs319,993 shsPBLAPanbela Therapeutics$0.44+7.3%$0.75$0.40▼$477.00$1.43M1.4873,274 shs25,779 shsTENXTenax Therapeutics$3.51-1.4%$3.97$3.47▼$61.20$6.97M2.2540,878 shs11,205 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics+24.07%-13.08%-22.52%-22.00%-87.14%CYTOAltamira Therapeutics+11.11%+6.67%-33.88%-19.60%-92.31%PBLAPanbela Therapeutics+7.29%-10.11%-31.25%-89.70%-99.87%TENXTenax Therapeutics-1.40%-4.62%-6.15%-65.00%-86.54%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATXIAvenue Therapeutics0.9964 of 5 stars0.05.00.04.62.00.00.0CYTOAltamira Therapeutics1.4943 of 5 stars0.05.00.00.03.10.81.3PBLAPanbela Therapeutics0.7049 of 5 stars3.50.00.00.00.00.00.6TENXTenax Therapeutics3.0643 of 5 stars3.55.00.00.02.90.01.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXIAvenue Therapeutics3.00BuyN/AN/ACYTOAltamira TherapeuticsN/AN/AN/AN/APBLAPanbela Therapeutics3.00Buy$500.00113,536.36% UpsideTENXTenax Therapeutics3.00Buy$480.0013,575.21% UpsideCurrent Analyst RatingsLatest PBLA, TENX, CYTO, and ATXI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024PBLAPanbela TherapeuticsRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy2/20/2024TENXTenax TherapeuticsRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXIAvenue TherapeuticsN/AN/AN/AN/A$0.03 per shareN/ACYTOAltamira Therapeutics$320K7.90N/AN/A$4.56 per share0.35PBLAPanbela TherapeuticsN/AN/AN/AN/A($18.37) per shareN/ATENXTenax TherapeuticsN/AN/AN/AN/A$27.15 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXIAvenue Therapeutics-$10.38M-$1.27N/A∞N/AN/AN/A-335.11%5/10/2024 (Estimated)CYTOAltamira Therapeutics-$4.31MN/A0.00N/AN/AN/AN/AN/A7/10/2024 (Estimated)PBLAPanbela Therapeutics-$25.26M-$669.09N/AN/AN/AN/A-70,194.55%-172.92%5/2/2024 (Estimated)TENXTenax Therapeutics-$7.71MN/A0.00N/AN/AN/A-65.79%-58.31%5/20/2024 (Estimated)Latest PBLA, TENX, CYTO, and ATXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023PBLAPanbela Therapeutics-$24.34-$65.90-$41.56-$65.90N/AN/A3/18/2024Q4 2023ATXIAvenue TherapeuticsN/A$0.56+$0.56$0.56N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXIAvenue TherapeuticsN/AN/AN/AN/AN/ACYTOAltamira TherapeuticsN/AN/AN/AN/AN/APBLAPanbela TherapeuticsN/AN/AN/AN/AN/ATENXTenax TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXIAvenue TherapeuticsN/A1.551.55CYTOAltamira TherapeuticsN/A1.381.38PBLAPanbela TherapeuticsN/A0.250.25TENXTenax TherapeuticsN/A3.263.26OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXIAvenue Therapeutics17.34%CYTOAltamira Therapeutics1.91%PBLAPanbela Therapeutics4.37%TENXTenax Therapeutics1.67%Insider OwnershipCompanyInsider OwnershipATXIAvenue Therapeutics1.80%CYTOAltamira Therapeutics13.03%PBLAPanbela Therapeutics0.01%TENXTenax Therapeutics1.85%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATXIAvenue Therapeutics344.26 million43.46 millionNot OptionableCYTOAltamira Therapeutics101.58 million1.37 millionNot OptionablePBLAPanbela Therapeutics63.48 million3.48 millionNot OptionableTENXTenax Therapeutics51.96 million1.92 millionNot OptionablePBLA, TENX, CYTO, and ATXI HeadlinesSourceHeadlineTENX: 2023 Financial Resultsfinance.yahoo.com - April 9 at 12:56 PMTenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”globenewswire.com - April 9 at 8:30 AMTenax Therapeutics: Q4 Earnings Insightsbenzinga.com - March 28 at 10:25 PMTENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023msn.com - March 28 at 10:25 PMTenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Resultsglobenewswire.com - March 28 at 8:30 AMFormer public company CEO now leads RTP firmbizjournals.com - March 20 at 8:28 PMTenax Therapeutics to Present at the 36th Annual Roth Conferenceglobenewswire.com - March 12 at 8:30 AMTenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024globenewswire.com - February 29 at 9:00 AMTenax acquires global rights to oral, subcutaneous levosimendanpulmonaryhypertensionnews.com - February 21 at 5:58 PMTenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendanfinance.yahoo.com - February 20 at 9:56 AMTenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendanglobenewswire.com - February 20 at 8:30 AMTENX: First Patient Enrolledfinance.yahoo.com - February 12 at 3:34 PMChapel Hill pharma pushing PHT treatment opens $9M stock offeringbizjournals.com - February 9 at 5:08 PMWhy Tenax Therapeutics (TENX) Stock Is Getting Obliteratedmsn.com - February 8 at 4:05 PMTenax Therapeutics Shares Plummet Premarket After Stock Offeringmarketwatch.com - February 8 at 11:05 AMTenax Therapeutics Announces Pricing Of About $9 Mln Offering Of Shares, Warrants; Stock Tanks 63%markets.businessinsider.com - February 8 at 11:05 AMTenax Therapeutics Announces Pricing of Approximately $9 Million Public Offeringfinance.yahoo.com - February 8 at 11:05 AMWhy Is Tenax Therapeutics (TENX) Stock Down 64% Today?investorplace.com - February 8 at 10:03 AMTenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)finance.yahoo.com - February 8 at 12:17 AMTenax Therapeutics Granted Patent for Heart Treatment Drugsmsn.com - February 7 at 9:17 AMTenax Shares Surge After Acceptance of Patent Applicationmarketwatch.com - February 6 at 2:06 PMTenax surges after patent win for heart failure therapymsn.com - February 6 at 2:06 PMTenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)finance.yahoo.com - February 6 at 9:06 AMTenax Therapeutics Stock (NASDAQ:TENX), Short Interest Reportbenzinga.com - January 3 at 11:27 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAvenue TherapeuticsNASDAQ:ATXIAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Altamira TherapeuticsNASDAQ:CYTOAltamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.Panbela TherapeuticsNASDAQ:PBLAPanbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.Tenax TherapeuticsNASDAQ:TENXTenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.